• Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technology
• MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharma Inc. (Rose Pharma) today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management. ROSE-010 is an investigational, rapid-acting glucagon-like peptide-1 (GLP-1) receptor agonist that will be formulated using MannKind’s proprietary Technosphere dry-powder inhalation technology. The companies intend to evaluate whether a rapid-acting, short-duration inhaled GLP-1 may offer a flexible approach to weight management.

Under the agreement, Rose Pharma received an exclusive, worldwide license to use MannKind’s Technosphere technology to develop and commercialize ROSE-010 Technosphere. MannKind will support formulation development and advancement of the program through pharmaceutical development services to completion of Phase 1b in weight management.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.